A speaker at the Heart in Diabetes CME Conference presented evidence that combining GLP-1 receptor agonists with SGLT2 inhibitors may provide additive cardiovascular and renal benefits in type 2 diabetes. A 2025 meta-analysis of 18 cohort studies found lower risks of major adverse cardiovascular events and all-cause mortality with combination therapy versus monotherapy. No formal outcome trial of the combination is expected, so observational data inform current guidance.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.